Tivdak Patient Assistance Program

(tisotumab vedotin-tftv)

Key Takeaways

  1. Tivdak (tisotumab vedotin-tftv) is a tissue factor-directed antibody-drug conjugate used to treat adults with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
  2. Tivdak targets tissue factor on cancer cells and delivers MMAE inside the cell, disrupting microtubules and promoting cancer-cell death.
  3. Prescription Hope may help eligible patients navigate medication assistance options for Tivdak and other prescription medications.

Introduction

Tivdak (tisotumab vedotin-tftv) is a tissue factor-directed antibody-drug conjugate used to treat adults with recurrent or metastatic cervical cancer when the disease has progressed on or after chemotherapy.

Tivdak is administered by intravenous infusion and requires specific eye-care measures because of its risk of serious ocular toxicity. For patients facing the costs and administrative requirements associated with treatment, Prescription Hope may provide Tivdak medication assistance to eligible patients navigating access to their prescribed treatment.

What Is the Tivdak Patient Assistance Program?

Understanding Tivdak Prescription Assistance

Brand-name medication manufacturers understand that some of their medications may be more expensive than the average American can afford.

Patient assistance programs help eligible patients who have difficulty affording prescribed medications get access to their needed medications.

Unfortunately, some of these programs require complex application steps, including phone calls, document collection, signature gathering, and more.

Prescription Hope provides Tivdak prescription assistance services for patients seeking medication assistance through patient assistance programs and can help simplify the process of navigating applicable assistance programs.

Eligibility requirements vary by program. Patients may need to provide information about their prescription, insurance status, income, and other circumstances. Prescription Hope advocates can help patients understand the application process and coordinate the information needed to seek assistance.

How Expert Advocates Help Make Tivdak More Affordable

Personalized Medication Assistance

Prescription Hope advocates can help eligible patients navigate the Tivdak assistance program process. This may include helping patients understand application requirements, gathering necessary documentation, and coordinating information between the patient, healthcare provider, and applicable assistance program.

Personalized Tivdak affordability help can make the administrative process easier to navigate while patients focus on their treatment.

Ongoing Patient Support

Seeking medication assistance may involve more than completing an initial application. Patients may need continued Tivdak patient support with documentation, renewals, or other program requirements.

Prescription Hope provides ongoing prescription support to help eligible patients navigate these requirements and continue seeking access to prescription medications when applicable program criteria are met.

Tivdak Price Comparison

vs

Prescription Hope logo

Estimated Retail Price*

$7,518.94

30-Day Supply

Prescription Hope Price

$70

Per Month, NO Matter The Retail Price

*Source: Drugs.com

Navigating Treatment Costs

The cost of cancer treatment can create an additional challenge for patients and families. Prescription Hope can provide Tivdak cost assistance to eligible patients navigating medication assistance options.

Prescription Hope’s service is available at $70.00 per month, per medication. Patients must still meet the applicable requirements for medication assistance.

Tivdak Patient Assistance Eligibility

General Eligibility Requirements

Eligibility for medication assistance varies by program. General eligibility requirements that may be considered include income, insurance status, having a valid prescription, and U.S. residency.

Prescription Hope can help patients understand the information that may be required when seeking assistance. Submitting an application does not guarantee approval, and patients must meet the requirements of the applicable assistance program.

Simple Enrollment With Expert Support

Getting Started With Enrollment

Prescription Hope helps simplify the Tivdak assistance application process by guiding patients through the necessary steps:

  1. Submit Information: Provide the information needed to begin the assistance process.
  2. Advocate Contact: A Prescription Hope advocate reviews the information and helps explain the next steps.
  3. Document Collection: Gather the required patient and prescription documentation.
  4. Provider Coordination: Prescription Hope may coordinate with the healthcare provider when additional information is needed.
  5. Program Submission: Required materials are submitted to the applicable medication assistance program.
  6. Medication Delivery: If the patient qualifies and the application is approved, the medication can proceed through the applicable fulfillment process.

This Tivdak enrollment help can reduce the administrative burden associated with seeking prescription assistance.

Understanding Tivdak

How Tivdak Works

Tivdak contains tisotumab vedotin-tftv, a tissue factor-directed antibody-drug conjugate. Its antibody component is a human IgG1-kappa antibody directed against tissue factor and is linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE).

Tisotumab vedotin-tftv targets tissue factor expressed on cancer cells. After binding to tissue factor, the antibody-drug conjugate and tissue factor complex is internalized. A protease-cleavable linker then releases MMAE inside the cell.

MMAE disrupts the microtubule network of actively dividing cells, causing cell-cycle arrest and apoptotic cell death. Tivdak may also contribute to antitumor activity through antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity.

What Conditions Does Tivdak Treat?

Tivdak is indicated for adults with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

The pivotal Phase 3 innovaTV 301 trial included patients with recurrent or metastatic cervical cancer who had received one or two prior systemic treatment regimens in the recurrent or metastatic setting. This describes the population studied in the trial and does not establish a specific number of prior chemotherapy regimens as a requirement in the FDA-approved indication.

Benefits of Treatment

In the randomized Phase 3 innovaTV 301 trial, Tivdak significantly improved overall survival, progression-free survival, and objective response rate compared with investigator’s-choice chemotherapy.

Important Safety Information and Side Effects

Tivdak has a boxed warning for ocular toxicity. It can cause severe ocular adverse reactions, including changes in vision, severe vision loss, and corneal ulceration.

An ophthalmic examination is required before treatment, before every cycle for the first nine cycles, and as clinically indicated. Required eye care and premedication must be followed before, during, and after each infusion.

Ocular Adverse Reactions

Ocular adverse reactions, including conjunctivitis, keratopathy, dry eye, and other eye-related reactions, can occur with this medication and may lead to vision changes or corneal ulceration.

Ocular adverse reactions occurred in 55% of patients in clinical trials. Because of this risk, Tivdak treatment includes an active eye-care protocol with ophthalmic examinations and specific eye drops and cooling measures.

Peripheral Neuropathy

Peripheral neuropathy occurred in 39% of patients and can become severe. Treatment may need to be withheld, dose-reduced, or permanently discontinued if peripheral neuropathy occurs.

Hemorrhage

Hemorrhage occurred in 51% of patients. Serious bleeding can occur, and pulmonary or central nervous system hemorrhage requires permanent discontinuation of Tivdak.

Pneumonitis

Severe, life-threatening, or fatal pneumonitis can occur with Tivdak.

Severe Cutaneous Adverse Reactions

Serious skin reactions, including potentially fatal Stevens-Johnson syndrome, can occur with this medication.

Embryo-Fetal Toxicity

Tivdak can cause fetal harm. Females of reproductive potential should use effective contraception during treatment and for 2 months after the last dose. Male patients with female partners of reproductive potential should use effective contraception during treatment and for 4 months after the last dose.

Pregnancy status should be verified before treatment in females of reproductive potential.

There are no data regarding the presence of this medication in human milk or its effects on the breastfed child or milk production. Women should not breastfeed during treatment and for 3 weeks after the last dose.

Common Side Effects

The most common adverse reactions and laboratory abnormalities occurring in 25% or more of patients in the pooled safety population included:

  • Decreased hemoglobin
  • Peripheral neuropathy
  • Conjunctival adverse reactions
  • Nausea
  • Fatigue
  • Increased AST
  • Nosebleeds (epistaxis)
  • Hair loss (alopecia)
  • Increased ALT
  • Hemorrhage

Drug Interactions

No clinical drug-interaction studies have been conducted with Tivdak. Unconjugated MMAE is primarily metabolized by CYP3A4.

Strong CYP3A4 inhibitors can increase MMAE exposure, so patients receiving these medications should be closely monitored for adverse reactions.

Contraindications

No contraindications are listed in the current U.S. prescribing information.

Access to Multiple Medications

Support Beyond Tivdak

Patients seeking prescription medication assistance may also need support accessing other prescription medications. Prescription Hope can help eligible patients navigate patient assistance programs beyond a single prescription.

Why Choose Prescription Hope for Brand-Name Medication Assistance

Patient-Focused Medication Support

Prescription Hope provides patient assistance support for people seeking access to prescription medications. Advocates can help eligible patients navigate the application process and understand the information needed to seek assistance.

This patient-focused medication assistance can help simplify the administrative steps involved in seeking access to a prescribed treatment.

Simplified Access to Specialty Therapies

This medication is a specialized antibody-drug conjugate used to treat recurrent or metastatic cervical cancer. Prescription Hope may provide specialty medication assistance to eligible patients seeking access to their prescribed treatment.

By providing tisotumab vedotin access support, Prescription Hope may help eligible patients navigate the requirements and administrative steps associated with seeking medication assistance.

Ongoing Prescription Assistance

Prescription Hope’s support can extend beyond the initial application process. Eligible patients may receive ongoing medication assistance as they navigate documentation, renewals, and other requirements associated with prescription assistance.

For patients prescribed Tivdak, this prescription assistance for cervical cancer can simplify the administrative process of seeking medication assistance while they focus on their treatment.

 

Frequently Asked Questions

It's Easy!

Submit Enrollment Form

Getting started is free and easy! Simply complete the online enrollment form. 

Receive Welcome Call

An Enrollment Specialist will reach out to you for a personalized welcome call.

We Manage The Process

Your dedicated team manages your account month after month, allowing you to focus on what matters most—your health.

Helpful Articles

Latest News & Stories

Save Money On Your Prescriptions Today!